Guo Marissa, Watanabe Tatsuya, Shinoka Toshiharu
Center for Regenerative Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
J Funct Biomater. 2025 Apr 23;16(5):152. doi: 10.3390/jfb16050152.
Stem cell-based therapies are an emerging treatment modality aimed at replenishing lost cardiomyocytes and improving myocardial function after cardiac injury. This review examines the current state of research on injectable stem cell therapies in the setting of cardiovascular disease given their relative simplicity and ability for deep myocardial tissue penetration. Various methods of cell delivery, ranging in level of invasiveness and procedural complexity, have been developed, and numerous cell types have been studied as potential sources of stem cells, each with distinct advantages and disadvantages. We discuss key challenges associated with this approach, including low stem cell retention after transplantation and the innovative biomolecular strategies that have been explored to address this issue. Overall, investigations into the application of stem cells toward cardiac regeneration remain predominantly in the preclinical stage with a number of small, early-phase clinical trials. However, continued scientific advancements in stem cell technology may provide transformative treatment options for patients with heart failure, offering improved survival and quality of life.
基于干细胞的疗法是一种新兴的治疗方式,旨在补充受损后丢失的心肌细胞并改善心脏功能。鉴于可注射干细胞疗法相对简单且能够深入心肌组织,本综述探讨了其在心血管疾病治疗中的研究现状。目前已开发出多种细胞递送方法,其侵入性和操作复杂性各不相同,并且已经研究了多种细胞类型作为干细胞的潜在来源,每种细胞类型都有各自的优缺点。我们讨论了与这种方法相关的关键挑战,包括移植后干细胞保留率低的问题,以及为解决该问题而探索的创新生物分子策略。总体而言,干细胞在心脏再生方面的应用研究主要仍处于临床前阶段,仅有一些小型的早期临床试验。然而,干细胞技术的持续科学进步可能为心力衰竭患者提供变革性的治疗选择,提高生存率和生活质量。